Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment

NCT02042885 is registered in ClinicalTrials.gov with Otsuka Novel Products GmbH as lead sponsor.

NCT NCT02042885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02042885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment
Lead sponsor
Otsuka Novel Products GmbH
Phase
Phase 1/2
Overall status
Terminated
Start date
January 31, 2014
Completion date
February 28, 2015
Enrollment
79 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, endometrial cancer, ovarian cancer, prostate cancer, salivary gland cancer, squamous cell carcinoma of the cervix